# Synchron: company

Canonical ID: `ac5afad9-cfd5-4b66-aa18-4d3aacf16560`

## Key facts

- **CEO:** Tom Oxley (Founder, neurologist, Mount Sinai)
- **Total funding:** over $345M ($200M Series D 2024, $75M Series C 2022)
- **Product:** Stentrode (endovascular BCI implant, no open-brain surgery)
- **Clinical trials:** COMMAND (US, FDA-approved), SWITCH (Australia, 4 patients)
- **Safety:** No serious device-related adverse events in 6 patients
- **Target:** Patients with severe paralysis (ALS) to communicate via thought

- **Slug:** synchron
- **Founded:** 2016
- **HQ:** New York, NY, USA
- **Funding total (USD):** 200000000

## Models

- [Synchron Stentrode](/models/synchron-stentrode.md) (wearable) (id: `b1b7a2ef-267c-4571-a478-e999c75a5560`)

## Current leadership (1)

- [Tom Oxley](/people/tom-oxley.md) Founder & CEO (_reported, not verified_)

## Founders (1)

- [Tom Oxley](/people/tom-oxley.md) (cofounder)

## Supplies to

_No verified supply relationships on file. Supply-chain coverage is being added across the registry; check back as the seed populates this company's outbound edges._

_Outbound supply edges. Each appears when verified with at least two strong sources. Sources are append-only; corrections add new sources rather than rewrite history._

## Sources (1)

1. https://www.facebook.com/synchroninc/videos/-big-news-fda-approval-granted-for-synchrons-intent-trial-the-intent-trial-will-/2984514821739037/

_API: GET /v1/companies/ac5afad9-cfd5-4b66-aa18-4d3aacf16560 · canonical URL: /companies/synchron_